Statistical analysis plan for evaluating low- vs. Standard-dose alteplase in the ENhanced Control of Hypertension and Thrombolysis strokE stuDy (ENCHANTED)

International Journal of Stroke

Volumn 10, Issue 8, 2015, Pages 1313-1315

  Anderson, Craig S ^a   Woodward, Mark ^a   Arima, Hisatomi ^a,b   Chen, Xiaoying ^a   Lindley, Richard I ^a   Wang, Xia ^a   Chalmers, John ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

acute; alteplase; clinical trials; statistical analysis plan; stroke; thrombolysis

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BLOOD PRESSURE; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; HUMAN; HYPERTENSION; LOW DRUG DOSE; OPEN STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STATISTICAL ANALYSIS; THROMBOSIS; CEREBRAL HEMORRHAGE; DOSE RESPONSE; SINGLE BLIND PROCEDURE; STROKE;

BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYTIC AGENTS; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84954403333     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/ijs.12602     Document Type: Article

References (18)

1. The National Institute of Disorders and Stroke rt-PA Stroke Study group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333:1581-7.
2. Emberson J, Lees KR, Lyden P,. Effect of treatment delay, age and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014; 384:1929-35.
3. Wardlaw JM, Murray V, Berge E,. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 2012; 379:2364-72.
4. Brott TG, Haley EC, Jr. Levy DE,. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992; 23:632-40.
5. Haley EC, Jr. Levy DE, Brott TG,. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 1992; 23:641-5.
6. Haley EC, Jr. Brott TG, Sheppard GL,. Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke: the TPA Bridging Study Group. Stroke 1993; 24:1000-4.
7. Mori E, Yoneda Y, Tabuchi M,. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992; 42:976-82.
8. Yamaguchi T, Kikuchi H, Hayakawa H,. Clinical efficacy and safety of intravenous tissue plasminogen activator in acute ischaemic stroke; in Yamaguchi T, Mori E, Minematsu K, del Zoppo GJ, (eds): Thrombolytic Therapy in Acute Ischaemic Stroke III. Tokyo, Springer-Verlag, 1995:223-9.
9. Yamaguchi T, Mori E, Minematsu K,. Alteplase at 0·6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke 2006; 37:1810-5.
10. Sharma VK, Ng KW, Venketasubramanian N,. Current status of intravenous thrombolysis for acute ischemic stroke in Asia. Int J Stroke 2011; 6:523-30.
11. Pandian JD, Srikanth V, Read SJ, Thrift AG,. Poverty and stroke in India: a time to act. Stroke 2007; 38:3063-9.
12. Tsai CF, Thomas B, Sudlow CLM,. Epidemiology of stroke and its subtypes in Chinese vs white populations: a systematic review. Neurology 2013; 81:264-72.
13. Menon BK, Saver JL, Prabhakaran S,. Risk score for intracranial haemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator. Stroke 2012; 43:2293-9.
14. Wardlaw JM, Koumellis P, Liu M,. Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke. Cochrane Database Syst Rev 2013; (5):Art. No.: CD000514. doi: 10.1002/14651858.CD000514.pub.
15. Anderson CS, Huang Y, Wang JG,. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurol 2008; 7:391-9.
16. Huang Y, Sharma VK, Robinson T,. Rationale, design, and progress of the ENhanced Control of Hypertension ANd Thrombolysis strokE stuDy (ENCHANTED) trial: an international multicenter 2 × 2 quasi-factorial randomized controlled trial of low-vs. standard-dose rt-PA and early intensive vs. guideline-recommended blood pressure lowering in patients with acute ischaemic stroke eligible for thrombolysis treatment. Int J Stroke 2015; 10:778-88.
17. Anderson CS, Heeley E, Huang Y,. Rapid blood pressure lowering in acute intracerebral hemorrhage. N Engl J Med 2013; 368:2355-65.
18. Mulla SM, Scott IA, Jackevicius CA, You JJ, Guyatt GH,. How to use a noninferiority trial: users' guides to the medical literature. JAMA 2012; 308:2605-11.